Zions Bancorporation’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$16.9K Hold
74
﹤0.01% 531
2024
Q3
$18.1K Sell
74
-8
-10% -$1.79K ﹤0.01% 530
2024
Q2
$15.7K Buy
82
+8
+11% +$1.62K ﹤0.01% 590
2024
Q1
$14.7K Sell
74
-4
-5% -$733 ﹤0.01% 607
2023
Q4
$13.4K Sell
78
-22
-22% -$3.38K ﹤0.01% 603
2023
Q3
$14.8K Buy
100
+52
+108% +$9.4K ﹤0.01% 564
2023
Q2
$10.5K Sell
48
-6
-11% -$1.34K ﹤0.01% 629
2023
Q1
$11.8K Sell
54
-3
-5% -$651 ﹤0.01% 614
2022
Q4
$11.9K Buy
57
+5
+10% +$1.1K ﹤0.01% 670
2022
Q3
$11K Hold
52
﹤0.01% 656
2022
Q2
$11K Sell
52
-25
-32% -$5.32K ﹤0.01% 718
2022
Q1
$19K Buy
77
+24
+45% +$5.8K ﹤0.01% 683
2021
Q4
$14K Buy
53
+7
+15% +$1.82K ﹤0.01% 696
2021
Q3
$12K Hold
46
﹤0.01% 702
2021
Q2
$11K Buy
46
+1
+2% +$210 ﹤0.01% 721
2021
Q1
$9K Buy
45
+6
+15% +$1.2K ﹤0.01% 733
2020
Q4
$8K Buy
39
+1
+3% +$199 ﹤0.01% 728
2020
Q3
$7K Buy
38
+14
+58% +$2.58K ﹤0.01% 761
2020
Q2
$5K Buy
24
+16
+200% +$2.62K ﹤0.01% 751
2020
Q1
$1K Hold
8
﹤0.01% 879
2019
Q4
$1K Hold
8
﹤0.01% 946
2019
Q3
$1K Hold
8
﹤0.01% 945
2019
Q2
$1K Buy
8
+4
+100% +$443 ﹤0.01% 880
2019
Q1
$0 Buy
+4
New +$413 ﹤0.01% 969

Other funds holding RMD

Zions Bancorporation's RMD Position: Q4 2024 in Review

Zions Bancorporation held its ResMed (RMD) position steady in Q4 2024 at 74 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #531.

Zions Bancorporation first reported a position in RMD in Q1 2019 and has held it in 24 quarters since. The position peaked at $19K in Q1 2022. 872 funds tracked by Wall St. Rank hold RMD as of Q4 2024.

  • Zions Bancorporation held 74 shares of ResMed worth $16.9K as of Q4 2024.
  • Zions Bancorporation left its ResMed share count unchanged in Q4 2024.
  • ResMed made up ﹤0.01% of Zions Bancorporation's portfolio in Q4 2024, its #531 holding.
  • Zions Bancorporation first reported a position in ResMed in Q1 2019 and has held it in 24 quarters since.
  • Zions Bancorporation's ResMed position peaked at $19K in Q1 2022.
  • 872 funds tracked by Wall St. Rank held ResMed as of Q4 2024.

Based on Zions Bancorporation's 13F filing for Q4 2024, filed 11 Feb 2025.